Business
Trading Statement
Trading Statement.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 0737J\n Sareum Holdings PLC\n 19 August 2021\n \n \n \n \n Sareum Holdings PLC \n \n \n (\"Sareum\" or the \"Company\") \n \n Trading Statement\n \n Cambridge, UK, 19 August 2021 - Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, provides the following trading update ahead of its full year results for the year ended 30 June 2021. Sareum expects to report its full audited annual results in October 2021.\n OPERATIONAL HIGHLIGHTS\n SDC-1801 for treating symptoms of Covid-19\n As noted in the Company's RNS announcement of 1 July 2021, the UKRI-funded Covid-19 research project for SDC-1801, a novel, TYK2/JAK1 inhibitor, was completed on schedule, with the final results confirming the initial encouraging results as noted in the Company's Interim Results, published on 23 April 2021.\n The project found that SDC-1801 reduced the levels of cytokines associated with Acute Respiratory Distress Syndrome (ARDS) in human lung cells infected with SARS-CoV-2 and demonstrated a profile that was superior to the anti-inflammatory steroid dexamethasone and similar to baricitinib, a JAK1/JAK2 inhibitor.\n The in-vivo studies that have now been completed support the initial cellular results and provide strong evidence that expression of Type 1 interferons (IFNa and IFNb) is reduced by SDC-1801 treatment in a dose-responsive manner. The studies also showed that viral loads did not increase after SDC-1801 administration, which is a potential concern when anti-inflammatory agents are used to dampen down an over-active immune response\n The Company aims to commence Phase 1 clinical trials for SDC-1801 in early 2022, subject to successful completion of the ongoing preclinical toxicology studies, gaining the requisite approval and financing. The timing and design of the clinical trials for Covid-19 applications will be determined following consultations with experts in the field.\n SDC-1801 (autoimmune diseases)\n \n Recent delays in compound supply mean that SDC-1801 is now scheduled to commence its final preclinical studies at the beginning of Q4 2021 but the Company still aims to file a Clinical Trial Application (CTA) by the end of Q4, subject to no further delays. First clinical trials -...